

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018

AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED ON 31<sup>ST</sup> MARCH, 2016

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

₹ in Lacs

Sr. No.	Particulars	Quarter Ended			Year Ended	
		Audited	Unaudited	Audited	Audited	Audited
		Current Year Mar - 2016	Current Year Dec - 2015	Previous Year March -2015	Current year ended 31/03/2016	Previous year ended 31/03/2015
PART-I						
1	Income From Operations					
a	Net Sales/ Income from Operations ( Net of Excise duty)	6,840.98	7,691.42	7,042.13	32,083.07	28,042.48
b	Other Operating Income	173.32	121.52	99.88	559.10	326.57
	Total Income from Operations (net):-	7,014.30	7,812.94	7,142.01	32,622.17	28,369.05
2	Expenditure					
a	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	906.32	(593.79)	747.13	(253.36)	212.08
b	Cost of Materials Consumed	4,232.64	6,656.12	4,821.54	24,892.62	21,821.62
c	Purchase of Stock -In-Trade	227.75	-	115.12	227.75	117.41
d	Employees Benefit Expense	159.87	170.08	144.97	657.74	582.46
e	Processing Charges	242.73	181.07	160.29	803.87	756.91
f	Power Fuel & Other Utility	47.94	107.42	77.42	347.68	322.19
g	Depreciation and amortisation expenses	57.52	62.99	187.06	225.88	327.35
h	Other Expenses	556.01	491.92	290.99	2,017.58	1,284.42
	Total Expenses :-	6,430.57	7,075.80	6,544.51	28,919.76	25,404.44
3	Profit From Operation before other income, Finance Costs & Exceptional Items (1-2)	583.73	737.13	597.50	3,702.41	2,964.61
4	a Other Income	129.18	61.94	148.31	350.65	504.88
	b Exchange Gain/(Loss)	(13.07)	(26.53)	(57.81)	(255.11)	(278.40)
5	Profit from ordinary activities before finance costs & Exceptional Items(3+4)	699.84	772.55	688.00	3,797.96	3,191.09
6	Finance Costs	3.00	1.03	2.81	4.25	5.02
7	Profit from ordinary activities after finance costs but before Exceptional Items(5-6)	696.85	771.52	685.18	3,793.71	3,186.07
8	Exceptional Items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before Tax (7+8)	696.85	771.52	685.18	3,793.71	3,186.07
10	Tax Expenses	183.28	250.00	186.95	1,213.28	986.95
11	Profit / (Loss) from ordinary activities after Tax (9-10)	513.57	521.52	498.23	2,580.43	2,199.12
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-	-
13	Profit / (Loss) for the period after Tax (after Extra ordinary Items) (11-12)	513.57	521.52	498.23	2,580.43	2,199.12
14	Share of profit / (Loss) of associates	-	-	-	-	-
15	Minority Interest	-	-	-	-	-
16	Net Profit(+) / Loss(-) after taxes, minority interest and share of profit of profit / (loss) of associates (13+14+15)	513.57	521.52	498.23	2,580.43	2,199.12
17	Paid up Equity Share Capital ( Face value of ₹ 5/- each)	1,252.80	1,252.80	417.60	1,252.80	417.60
18	Reserves excluding Revaluation Reserves as per Balance sheet of Previous Accounting Year				10,674.99	9,672.12
19	Earning per Share(EPS) Face Value of Rs.5/-					
	i Earning Per Share(before Extraordinary Items) (not annualised)					
	(a) Basic	2.05 #	2.08 #	5.97	10.30 #	26.33
	(b) Diluted	2.05 #	2.08 #	5.97	10.30 #	26.33
	ii Earning Per Share(after Extraordinary Items) (not annualised)					
	(a) Basic	2.05 #	2.08 #	5.97	10.30 #	26.33
	(b) Diluted	2.05 #	2.08 #	5.97	10.30 #	26.33

- The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on 27<sup>th</sup> May, 2016.
- The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".
- Corresponding figures of the previous quarter have been regrouped, to make them comparable wherever necessary.
- The figures for the quarter ended 31.03.2016 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.
- EPS reported at mark # is after giving effect to the issue of bonus share in the ratio of 2 bonus shares for each existing share. Hence, comparable EPS at mark # would be Rs. 6.15/- for the quarter ended on 31/03/2016, Rs.6.24/- for the quarter ended on 31/12/2015 and Rs. 30.90 for the year ended on 31/03/2016.
- The Board of Directors have recommended a final dividend of 10% i.e. Rs.0.50/- per Equity Share of Rs.5/- each for the year ended on March 31, 2016 subject to approval of the Shareholders at the ensuing Annual General Meeting. The Company had paid an interim dividend of 40% i.e. Rs. 2.00/- per Equity Share of Rs.5/- each. Accordingly, total dividend declared and recommended by the Company for the financial year 2015-16 is 50% Rs.2.50/- per Equity Shares of Rs.5/- each.

Place: Mumbai

Date: 27<sup>th</sup> MAY, 2016

For ANUH PHARMA LIMITED

*Pranav*

Managing Director

**ANUH PHARMA LIMITED**  
Statement of Assets and Liabilities

(₹ In Lakhs)

Particulars	Audited	
	As at March 31, 2016	As at March 31, 2015
<b>I. EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	1,252.80	417.60
(b) Reserves and surplus	10,674.99	9,672.12
	11,927.79	10,089.72
<b>2 Non-current liabilities</b>		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
(d) Long-term provisions	78.22	58.22
	78.22	58.22
<b>3 Current liabilities</b>		
(a) Short-term borrowings	210.77	-
(b) Trade payables	5,232.38	4,801.08
(c) Other current liabilities	272.31	199.54
(d) Short-term provisions	1,532.62	1,679.95
	7,248.08	6,680.58
<b>TOTAL</b>	<b>19,254.08</b>	<b>16,828.52</b>
<b>II. ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Fixed assets		
(i) Tangible assets	1,789.43	939.53
(ii) Intangible assets	42.26	9.61
(iii) Capital work-in-progress	18.80	33.04
(iv) Intangible assets under development	-	-
	1,850.49	982.17
(b) Non-current investments	2,102.67	1,327.39
(c) Deferred tax assets (net)	113.50	66.78
(d) Long-term loans and advances	83.85	96.92
(e) Other non-current assets	-	-
	4,150.51	2,473.26
<b>2 Current assets</b>		
(a) Current investments	2,194.54	2,932.71
(b) Inventories	2,368.98	1,642.05
(c) Trade receivables	7,467.03	6,815.03
(d) Cash and bank balances	1,338.35	1,415.39
(e) Short-term loans and advances	1,718.27	1,527.11
(f) Other current assets	16.40	22.97
	15,103.57	14,355.26
<b>TOTAL</b>	<b>19,254.08</b>	<b>16,828.52</b>

For ANUH PHARMA LIMITED



Managing Director